Decision support across the product lifecycle
Make the decisions that move development forward
Compare mechanisms, treatments and development scenarios before committing in the real world. Identify the patients most likely to respond, understand the drivers of efficacy and risk, and define the dose, regimen and trial strategy that give each program its strongest path forward.
Decide what to advance
Test whether biological mechanisms translate into differentiated treatment potential. Compare targets and candidates, explore combination strategies, and identify efficacy or safety risks before committing to clinical development.
Build the strongest path to proof
Compare doses, regimens, combinations, patient populations, endpoints and protocols against the relevant standard of care. Identify best responders and quantify uncertainty before the next costly trial.
Demonstrate and extend product value
Evaluate long-term outcomes across representative patient populations, substantiate differentiation, and generate evidence to support pivotal decisions, label expansion, external control arms and market access.
Improving R&D using AI-assisted mechanistic modeling
Across every stage of R&D, four ways we help.
Digital Twins
Predict patient outcomes through mechanistic simulation.
Nova's Digital Twins combine biology, pharmacology, clinical data, and artificial intelligence to create dynamic virtual representations of disease and treatment response.
- Virtual population generation
- Patient-level predictions
- Subgroup response prediction
- Go/no-go decision support
Model-informed trial design
Design smarter trials before enrolling the first patient.
Evaluate alternative protocols, dosing strategies, patient populations, and endpoints through predictive simulation. Nova helps sponsors compare development scenarios, optimize study design, and improve the probability of technical and regulatory success.
- Dose selection
- Protocol / adaptive design
- Endpoint evaluation
- Sample size optimization
- Scenario simulation
Synthetic / external control arms
Strengthen clinical evidence with mechanistic simulations.
When placebo-controlled studies are impractical or recruitment is limited, Nova combines historical clinical data with mechanistic disease models to generate scientifically grounded comparator populations that complement traditional clinical evidence.
- Historical data integration
- Comparator modeling
- Rare disease applications
Translational modeling
Bridge biology and clinical development.
Translate preclinical knowledge into confident clinical decisions through mechanistic PK/PD modeling, disease biology and Digital Twins. Nova supports programs from first-in-human studies through late-stage development by reducing translational uncertainty.
- First-in-human studies
- PK/PD translation
- IND-enabling decisions
- Clinical development strategy
- Dose & regimen optimization
Expert team: scientists, engineers, biologists, clinicians, and medical doctors
Disease and treatment models, including 12+ trained and validated in-house
Projects delivered across oncology, cardiology, hepatology, infectious diseases, and rare diseases
Get started on your next project with Nova
Discuss applications and solutions with our modeling experts.